Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Neogen sells testing kits and products that help companies and veterinarians keep food and animals safe.
Neogen makes the tests that catch problems before they reach your plate. If a meat processor wants to know whether a batch of beef is free of a dangerous bacterium, or a feed mill wants to screen grain for mold toxins, Neogen sells the kit, the swab, and the little plastic tray that give an answer in hours instead of days. Same idea on the animal side: tests that help a vet or a farmer figure out why a herd is sick, or whether a cow is pregnant.
The company splits its business into two big halves. Food Safety handles the testing side鈥攖hings like allergen checks, foodborne pathogen detection, and residue screening for grain and produce. Animal Safety covers veterinary instruments, wound care, and genetic testing for livestock and pets. Customers are the people who can't afford a bad batch: food producers, processors, and veterinarians. They pick Neogen because a fast, cheap test that stops a recall or a disease outbreak is worth far more than the test costs. Neogen grew for decades as a steady, profitable, roll-up-style operator, buying smaller testing and veterinary companies and folding them into its catalog. Its biggest move came in 2023, when it bought the food-safety testing business of 3M and combined it with its own in a joint venture. That deal roughly doubled the food safety side and gave Neogen the bigger global footprint, but it also loaded the company with debt and made the integration messier than expected鈥攁 good reminder that buying scale is easy and making it work is not.
Competitors include big lab and life-science players like Thermo Fisher Scientific on the food-safety side and a long list of veterinary suppliers on the animal side. Neogen's edge is its catalog breadth and distribution鈥攊t sells thousands of small items that customers reorder constantly, which builds sticky relationships. The risk is that it's a small player in a world of giants, and its recent acquisition-heavy strategy leaves it exposed if growth slows.
Saved answer 路 last researched 15 Nov 2026